Suppr超能文献

大脑中表达的超保守受体:一个孤儿受体家族的表达、功能、基序与进化

Superconserved receptors expressed in the brain: Expression, function, motifs and evolution of an orphan receptor family.

作者信息

Stäubert Claudia, Wozniak Monika, Dupuis Nadine, Laschet Céline, Pillaiyar Thanigaimalai, Hanson Julien

机构信息

Rudolf Schönheimer Institute of Biochemistry, Faculty of Medicine, Leipzig University, Leipzig, Germany.

Laboratory of Molecular Pharmacology, GIGA-Molecular Biology of Diseases, University of Liège, Liège, Belgium.

出版信息

Pharmacol Ther. 2022 Dec;240:108217. doi: 10.1016/j.pharmthera.2022.108217. Epub 2022 May 26.

Abstract

GPR27, GPR85 and GPR173 constitute a small family of G protein-coupled receptors (GPCR) that share the distinctive characteristics of being highly conserved throughout vertebrate evolution and predominantly expressed in the brain. Accordingly, they have been coined as "Superconserved Receptors Expressed in the Brain" (SREB), although their expression profile is more complex than what was originally thought. SREBs have no known validated endogenous ligands and are thus labeled as "orphan" receptors. The investigation of this particular category of uncharacterized receptors holds great promise both in terms of physiology and drug development. In the largest GPCR family, the Rhodopsin-like or Class A, around 100 receptors are considered orphans. Because GPCRs are the most successful source of drug targets, the discovery of a novel function or ligand most likely will lead to significant breakthroughs for the discovery of innovative therapies. The high level of conservation is one of the characteristic features of the SREBs. We propose herein a detailed analysis of the putative evolutionary origin of this family. We highlight the properties that distinguish SREBs from other rhodopsin-like GPCRs. We present the current evidence for these receptors downstream signaling pathways and functions. We discuss the pharmacological challenge for the identification of natural or synthetic ligands of orphan receptors like SREBs. The different SREB-related scientific questions are presented with a highlight on what should be addressed in the near future, including the confirmation of published evidence and their validation as drug targets. In particular, we discuss in which pathological conditions these receptors may be of great relevance to solve unmet medical needs.

摘要

GPR27、GPR85和GPR173构成了一个小的G蛋白偶联受体(GPCR)家族,它们具有在整个脊椎动物进化过程中高度保守且主要在大脑中表达的独特特征。因此,它们被称为“大脑中表达的超保守受体”(SREB),尽管它们的表达谱比最初认为的更为复杂。SREB尚无经过验证的内源性配体,因此被标记为“孤儿”受体。对这类未表征受体的研究在生理学和药物开发方面都具有很大的前景。在最大的GPCR家族,即视紫红质样或A类家族中,约有100种受体被认为是孤儿受体。由于GPCR是最成功的药物靶点来源,发现一种新功能或配体很可能会在创新疗法的发现方面带来重大突破。高度保守是SREB的特征之一。我们在此提出对该家族假定进化起源的详细分析。我们强调了SREB与其他视紫红质样GPCR的区别特性。我们展示了这些受体下游信号通路和功能的当前证据。我们讨论了鉴定像SREB这样的孤儿受体的天然或合成配体所面临的药理学挑战。提出了与SREB相关的不同科学问题,并着重强调了近期应解决的问题,包括对已发表证据的确认及其作为药物靶点的验证。特别是,我们讨论了在哪些病理条件下这些受体可能对于满足未满足的医疗需求具有重大意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验